Otsuka Pharmaceuticals could shell out over $400 million in total for the Asia-Pacific rights to 4D-150, which combines a ...

A whisper-thin chip, smart glasses and patient training are reshaping how older people live with central vision loss across ...

A tiny chip, smart glasses and months of training are rewriting what blindness means for older people with failing central ...

4D Molecular Therapeutics has sold the Asia-Pacific rights to its eye gene therapy to Otsuka Pharmaceutical, securing $85 ...

Second-generation anti-VEGF agents, like aflibercept 8 mg and faricimab, show improved efficacy and treatment durability in ...

A wireless microchip implanted beneath the retina improved vision in 81% of patients with advanced age-related macular ...

The Eli Lilly and Company will acquire Adverum Biotechnologies, according to a joint press release issued by the 2 companies.

Eli Lilly has agreed to acquire eye disease specialist Adverum Biotechnologies, bucking a recent trend of big pharma ...

A large propensity-matched retrospective cohort study showed a small but statistically significant 7% increase in new-onset ...

A new trial shows that a wireless subretinal implant, the PRIMA system, restored central vision in patients with geographic ...

Astellas Pharma (($ALPMF)) announced an update on their ongoing clinical study. Astellas Pharma is conducting a clinical study titled ‘A Phase ...

A photovoltaic retinal implant shows promise as a way to improve vision in patients with advanced age-related macular ...